Incyte pipeline at a glance (March 2026)
About the Incyte clinical program
Incyte has built a focused clinical portfolio around kinase inhibition — JAK, FGFR, and IDH — with growing programs in checkpoint inhibition and CSF1R-targeted therapy. Jakafi (ruxolitinib), the first JAK1/2 inhibitor approved, remains central across myelofibrosis, polycythemia vera, and acute/chronic graft-versus-host disease. Opzelura (ruxolitinib cream) extends the JAK franchise into dermatology — approved for atopic dermatitis and vitiligo, with ongoing trials in additional inflammatory skin conditions. Pemazyre (pemigatinib) pioneered FGFR inhibition in cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR1 rearrangements. Zynyz (retifanlimab), their PD-1 inhibitor, is approved in Merkel cell carcinoma and anal canal carcinoma, with expansion trials ongoing. Niktimvo (axatilimab), targeting CSF1R in chronic GvHD, represents a new mechanism in allogeneic transplant complications.
Key therapeutic areas
- Hematology (myelofibrosis, PV, GvHD)
- Oncology (FGFR, PD-1, IDH)
- Dermatology (atopic dermatitis, vitiligo)
- Bone marrow failure / transplant complications
- Solid tumors (cholangiocarcinoma, anal carcinoma)
Key pipeline programs
- Jakafi (ruxolitinib) — JAK1/2, myelofibrosis/PV/GvHD
- Opzelura (ruxolitinib cream) — JAK1/2, atopic dermatitis/vitiligo
- Pemazyre (pemigatinib) — FGFR1/2/3, cholangiocarcinoma/FGFR1 neoplasms
- Zynyz (retifanlimab) — PD-1, Merkel cell/anal carcinoma
- Niktimvo (axatilimab) — CSF1R, chronic GvHD
- INCB57643 — BET bromodomain, AML/solid tumors
Monitor the Incyte pipeline daily
Get alerts when Incyte registers new trials or updates existing protocols. Free 14-day trial — no credit card required.
Start Monitoring FreeTop Incyte trial indications
| Condition / Indication | Trials |
|---|---|
| ["Myeloproliferative Neoplasms"] | 5 |
| ["Hidradenitis Suppurativa (HS)"] | 5 |
| ["Chronic Graft-versus-host-disease"] | 5 |
| ["Solid Tumors"] | 3 |
| ["Hidradenitis Suppurativa"] | 3 |
| ["Healthy Participants"] | 3 |
| ["Prurigo Nodularis"] | 2 |
| ["Ovarian Cancer"] | 2 |
Why monitor Incyte's clinical trial activity
Incyte's JAK inhibitor expansion — particularly Jakafi combinations in myelofibrosis (with BCL-2, BET inhibitors) and Opzelura label expansions in dermatology — generates consistent new trial registrations. Their FGFR inhibitor portfolio (pemigatinib, futibatinib partnership) is closely tracked in cholangiocarcinoma and urothelial cancer by oncology BD teams.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Incyte's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks Incyte trials
- Sponsor normalization: Incyte may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Incyte pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Start Free TrialFrequently asked questions
What is Incyte's focus in hematology clinical trials?
Incyte's hematology pipeline is anchored by Jakafi (ruxolitinib) — with ongoing trials in myelofibrosis combination regimens (adding BCL-2 inhibitors, BET inhibitors, and PI3K inhibitors), polycythemia vera, and GvHD. Niktimvo (axatilimab), approved for chronic GvHD, represents a new mechanism extending into other fibrotic and inflammatory allograft complications.
How many Incyte trials are currently recruiting?
Based on current ClinicalTrials.gov data, 27 Incyte-sponsored trials are actively recruiting patients across hematology, oncology, and dermatology programs.
Can DataLookout alert me to new Incyte dermatology trials?
Yes. You can create a watchlist combining Incyte as the sponsor with dermatology indication keywords — atopic dermatitis, vitiligo, alopecia areata. DataLookout will deliver daily alerts when new Incyte trials matching those criteria are registered or when existing trial statuses change.